Track topics on Twitter Track topics that are important to you
Celltrion Healthcare will purchase more biosimilars from biomanufacturing partner Celltrion Inc. and expand its distribution network after raising one trillion Won ($888m) in an IPO.
Celltrion Healthcare's initial public offering, which is seen as the most anticipated biotech IPO in South Korea's Kosdaq market this...
South Korean biopharmaceutical firm Celltrion has showcased data supporting the efficacy and safety of…
Teva Pharmaceutical Industries Ltd.IR Contacts:United StatesKevin C. Mannix, 215-591-8912Ran Meir, 215-591-3033orIsraelTomer Amitai, 972 (3) 926-7656orPR Contacts:IsraelIris Beck ...
PETAH TIKVA (dpa-AFX) - Celltrion Inc. and Teva Pharmaceutical Industries Ltd. (TEVA) said that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for ...
PETAH TIKVA (dpa-AFX) - Celltrion Inc., a global biopharmaceutical company, and Teva Pharmaceutical Industries Ltd. (TEVA) announced that the U.S. Food and Drug Administration has accepted for rev...
South Korean biotechnology company Celltrion has announced advances in its biosimilar rituximab and trastuzumab programmes in China and Japan.
The FDA has accepted Celltrion and Teva Pharmaceutical Industries' biologics license application for CT-P10, a biosimilar to -More-